Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.47 |
| ▸ | MARK3 | P27448 | 8/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | SGK1 | O00141 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | HCK | P08631 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12418377 | 1.00 | IRAK4 (0.47) | IRAK4MARK3ROCK2SGK1CHEK1 | |
| SCHEMBL12379338 | 1.00 | IRAK4 (0.47) | IRAK4MARK3ROCK2SGK1CHEK1 | |
| SCHEMBL2295856 | 0.90 | IRAK4 (0.45) | IRAK4MARK3ROCK2SGK1CHEK1 | |
| SCHEMBL2295484 | 0.89 | MARK3 (0.57) | IRAK4MARK3ROCK2SGK1CHEK1 | |
| SCHEMBL2291268 | 0.89 | MARK3 (0.53) | IRAK4MARK3ROCK2SGK1CHEK1 | |
| SCHEMBL12419196 | 0.89 | MARK3 (0.53) | IRAK4MARK3ROCK2SGK1CHEK1 | |
| SCHEMBL12417983 | 0.89 | MARK3 (0.57) | IRAK4MARK3ROCK2SGK1CHEK1 | |
| SCHEMBL12379683 | 0.88 | MARK3 (0.55) | IRAK4MARK3ROCK2SGK1CHEK1 | |
| SCHEMBL2293452 | 0.87 | MARK3 (0.47) | IRAK4MARK3ROCK2SGK1CHEK1 | |
| SCHEMBL2355069 | 0.87 | MARK3 (0.47) | IRAK4MARK3ROCK2SGK1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518911-B2 | Pyrazolo[1,5-a]pyridines as MARK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | claimed |
| EP-2320737-B1 | PYRAZOLO-[1,5-A]-PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-17 | — | — | EP | claimed |
| US-20110195933-A1 | PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-11 | — | — | US | claimed |
| US-8518911-B2 | Pyrazolo[1,5-a]pyridines as MARK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518911-B2 | Pyrazolo[1,5-a]pyridines as MARK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2320737-B1 | PYRAZOLO-[1,5-A]-PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20110195933-A1 | PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195933-A1 | PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS | MARK3, MARK4, MARK1 | IRAK4 975/4885MARK3 1/4885ROCK2 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.